pf-04878691
Small moleculeexperimental
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2003 (NCT00095160)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Hepacivirus · Phase 1
- Hodgkin Disease · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Toll-like receptor 7AGONIST
TLR7 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 852a
- 852a
- 852a compound
- n-(4-(4-amino-2-ethyl-1h-imidazo(4,5-c)quinolin-1-yl)butyl)methanesulfonamide
- n-(4-(4-amino-2-ethyl-1h-imidazo(4,5c)quinolin-1-yl)butyl)methanesulfonamide
- pf-04878691
- pf-04878691
- pf-04878691
- s32865
- s 32865
- s-32865
- toll-like receptor 7 agonist 852a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00810758 | Phase 1 | Jan 1, 2009 | Pfizer |
| NCT00386594 | N/A | Oct 1, 2006 | 3M, University of Chicago |
| NCT00319748 | Phase 2 | Apr 1, 2006 | Pfizer, University of Minnesota |
| NCT00276159 | Phase 2 | Jan 1, 2006 | Pfizer, University of Minnesota |
| NCT00189332 | Phase 2 | Feb 1, 2005 | Pfizer |
| NCT00091689 | Phase 1 | Sep 1, 2004 | Pfizer |
| NCT00095160 | Phase 1 | Oct 1, 2003 | Pfizer, University of Minnesota |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 6 | 3 | 2 | 2003 |
| University of Minnesota | Academic/Hospital | 3 | 3 | 2 | 2003 |
| 3M | For profit | 1 | 0 | 1 | 2006 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2006 |
4 organizations
Page 1 / 1